Could chemo plus immunotherapy double the punch against tough lung cancers?
Disease control
Not yet recruiting
This phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…
Phase: PHASE3 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC